cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Solid Biosciences Inc
16 own
30 watching
Current Price
$8.88
$-0.32
(-3.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
219.01M
52-Week High
52-Week High
15.05000
52-Week Low
52-Week Low
1.81000
Average Volume
Average Volume
0.25M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization219.01M
icon52-Week High15.05000
icon52-Week Low1.81000
iconAverage Volume0.25M
iconDividend Yield--
iconP/E Ratio--
What does the Solid Biosciences Inc do?
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Solid Biosciences Inc make?
News & Events about Solid Biosciences Inc.
Globe Newswire
1 year ago
CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will participate in a fireside chat at Chardans 7th Annual Genetic ...
Globe Newswire
1 year ago
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with ...
Globe Newswire
1 year ago
CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the BMO Biopharma ...
Globe Newswire
1 year ago
CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the SVB Securities Global ...
Globe Newswire
1 year ago
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duchenne muscular dystrophy - - White paper submitted to the U.S...
Frequently Asked Questions
Frequently Asked Questions
What is Solid Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Solid Biosciences Inc shares?
plus_minus_icon
How can I buy Solid Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Solid Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Solid Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Solid Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Solid Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Solid Biosciences Inc?
plus_minus_icon
What percentage is Solid Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Solid Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$8.88
$-0.32
(-3.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00